Recent Developments in Combination Immunotherapy with Other Therapies and Nanoparticle-Based Therapy for...

Area of Science:

• Oncology
• Nanomedicine
• Immunotherapy

Background:

• Triple-negative breast cancer (TNBC) lacks specific receptors, limiting treatment options.
• Developing novel therapeutic strategies for TNBC is a critical unmet need.
• Current research explores immunotherapy, radiotherapy, targeted therapy, combination therapy, and nanotechnology.

Purpose of the Study:

• To review recent advancements in combination therapy and nanotechnology-based treatments for TNBC.
• To highlight the therapeutic potential of these novel approaches in preclinical and clinical settings.

Main Methods:

• Literature review of combination therapies (immunotherapy, chemotherapy, targeted therapy, radiotherapy) for TNBC.
• Review of nanotechnology-based therapies using nanoparticles for TNBC treatment.
• Analysis of preclinical and clinical data on treatment efficacy.

Main Results:

• Combination therapy, particularly with immunotherapy, demonstrates efficacy in preclinical and clinical TNBC studies.
• Nanotechnology-based therapies show promise in preclinical TNBC models, utilizing nanoparticles loaded with various therapeutic agents.
• These advanced modalities offer new avenues for overcoming TNBC treatment challenges.

Conclusions:

• Combination therapy and nanotechnology-based treatments represent the most promising future directions for TNBC management.
• Further research and clinical translation of these approaches are warranted to improve patient outcomes.
• These strategies offer hope for addressing the limitations of current TNBC therapies.